You can buy or sell RDY and other stocks, options, ETFs, and crypto commission-free!
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. Read More It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others. The Global Generics segment is consist of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The PSAI segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.
52 Week High
52 Week Low
Advertising and Marketing
Simply Wall StMar 15
Should Dr. Reddy’s Laboratories (NSE:DRREDDY) Be Disappointed With Their 21% Profit?
If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly boost your returns by picking above-average stocks. To wit, the Dr. Reddy’s Laboratories Limited (NSE:DRREDDY) share price is 21% higher than it was a year ago, much better than the market return of around -0.9% (not including dividends) in the same period. If it can keep that out-performance up over the long term, investors will do very well! Unfortunately the longer term returns are not so ...
Simply Wall StFeb 28
Why Dr. Reddy’s Laboratories Limited’s (NSE:DRREDDY) High P/E Ratio Isn’t Necessarily A Bad Thing
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We’ll show how you can use Dr. Reddy’s Laboratories Limited’s (NSE:DRREDDY) P/E ratio to inform your assessment of the investment opportunity. Based on the last twelve months, Dr. Reddy’s Laboratories’s P/E ratio is 25.12. That is equivalent to an earnings yield of about 4.0%. Check out our latest analysis for Dr. Reddy’s Laboratories How Do I Calculate Dr. Reddy’s Laboratories’s Price To Earnings Rati...
Stock Price, News, & Analysis for Dr.Reddy's Laboratories
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics...
Expected May 22, Pre-Market